English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 25 September 2024, 21:00 HKT/SGT
Share:
    

Source: GEN Pharmaceuticals
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

ANKARA, Turkey, Sept 25, 2024 - (ACN Newswire) - GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. The findings were presented at Amsterdam's European Academy of Dermatology and Venereology (EADV) 2024 Congress.

GEN PharmaceuticalsGEN Pharmaceuticals
GEN Pharmaceuticals Manufacturing Facility

This multicenter, randomized, double-blind, placebo-controlled Phase 2 study involved 190 patients across 19 clinical centers in Türkiye. Patients were treated with GN-037clobetasol 17-propionate, or placebo twice daily for four weeks, followed by an additional four-week observation period. The study demonstrated GN-037's statistically significant superiority in reducing psoriasis symptoms compared to placebo, positioning it as a promising new treatment option for psoriasis patients worldwide.

Key Findings:

  • The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator's Global Assessment (IGA) score and achieving an IGA score of 0 or 1.
  • 37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006).
  • GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008)plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo.
  • 31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009).
  • No new safety concerns emerged with similar treatment-emergent adverse events across all arms.

Abidin Gülmüs, Chairman of GEN, stated: "We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community."

Nadir Ulu, MD, PhD, Vice President of R&D, added: "Our Phase 2 trial results highlighted GN-037's potential to improve patient outcomes significantly, and it may provide a novel, well-tolerated treatment option for patients with mild to moderate plaque psoriasis."

About GEN:

Founded in 1998, GEN is Türkiye's leading speciality pharmaceutical company. It is focused on developing innovative therapies across multiple therapeutic areas, with significant R&D investments and a commitment to advancing global healthcare. GEN actively works in both in-licensing and out-licensing business models. GEN partners with leading global pharmaceutical companies to bring innovative therapies and rare solutions to communities in its countries. It also develops and produces highly demanded and competitive therapeutic products in its GMP-certified manufacturing facility to bring therapy solutions required in international markets.

For more information, visit www.genilac.com.tr.

For inquiries:
Bulutay GÜNES, Head of Corporate Brand, b.gunes@genilac.com
Ali KETENCIOGLU, Investor Relations Manager, a.ketencioglu@genilac.com

Contact Information

Bulutay Gunes
Head of Corporate Brand
b.gunes@genilac.com

Ali Ketencioglu
Investor Relations Manager
a.ketencioglu@genilac.com

SOURCE: GEN Pharmaceuticals



Topic: Press release summary
Source: GEN Pharmaceuticals

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany  
July 9, 2025 22:00 HKT/SGT
Cornerstone Robotics Launches First Clinical Evaluation of Hong Kong-Developed Surgical Robotic System in UK  
July 9, 2025 20:32 HKT/SGT
Standard Chartered GBA Business Confidence Survey points to further tariff drag in H2  
July 9, 2025 18:55 HKT/SGT
Malaysia and France Strengthen Defence Industry Ties with Landmark MoU Signing  
July 9, 2025 12:08 HKT/SGT
GMG Commencing Sales of G(R) Lubricant and Advancing Regulatory Approvals  
July 9, 2025 09:00 HKT/SGT
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program  
Tuesday, July 8, 2025 7:30:00 PM
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment  
Tuesday, July 8, 2025 8:31:00 AM
Progress towards potassium-ion batteries  
July 8, 2025 06:48 HKT/SGT
Kincora Secures Strategic North American Investors and Announces Private Placement  
July 8, 2025 06:39 HKT/SGT
Small Businesses Embrace Social -- But Could be Missing a Trick in the Age of AI  
July 8, 2025 06:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575